LDHA and neoplasm: Therefore, an ideal ALDH‐targeting inhibitor should be nontoxic and well tolerated that can be safely administered by patients and in combination with conventional therapies, such as chemotherapy, radiotherapy, and immunotherapy to improve disease control over non‐CSC, bulk tumor cells.